Oncopeptides AB Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Oncopeptides AB stock has a consensus rating of "Hold" and an average price target of kr 2.50. The average 1-year stock price forecast is 48.63% higher than the current stock price, while the lowest is kr 2.10 (+24.85%) and the highest is kr 3.10 (+84.30%).

Price Target: kr 2.50 (+48.63%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	kr 2.10	kr 2.50	kr 2.30	kr 3.10
Change	+24.85%	+48.63%	+36.74%	+84.30%

Analyst Ratings

The average analyst rating for Oncopeptides AB stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Nov '25	Jan '26	May '26
Strong Buy	0	0	0
Buy	0	0	0
Hold	1	1	1
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	1

Financial Forecast

Revenue This Year

168.97M

from 71.12M

137.59%

from 71.12M

Revenue Next Year

289.10M

from 168.97M

71.10%

from 168.97M

EPS This Year

-0.41

from -1.10

EPS Next Year

-0.06

from -0.41

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	118.30M	8.36M	35.22M	31.65M	71.12M	168.97M
Revenue Growth	-	-92.94%	321.54%	-10.14%	124.72%	137.59%
Gross Profit	65.17M	8.35M	36.30M	28.99M	68.67M	161.79M
Gross Margin	55.09%	99.93%	103.06%	91.59%	96.55%	95.75%
Operating Income	-1.49B	-346.94M	-252.79M	-282.59M	-225.64M	-125.63M
Net Income	-1.43B	-337.95M	-249.11M	-284.61M	-249.59M	-125.83M
EPS	-	-	-	-	-1.10	-0.41
Free Cash Flow	-1.09B	-289.31M	-191.36M	-169.03M	-138.49M	-129.50M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.

Revenue Forecast

Revenue	2026	2027	2028
High	207.0M
Avg	169.0M
Low	127.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	191.1%
Avg	137.6%
Low	78.6%

EPS Forecast

EPS	2026	2027	2028
High	-0.37
Avg	-0.41
Low	-0.44

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-